ArticleDrug delivery2025
Nebulized inhalation of novel baicalein liposome based on phospholipid complex to alleviate acute lung injury.
Article in Drug delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting Ferroptosis in Sepsis: Therapeutic Potential and Mechanisms of Natural Products and Traditional Chinese Medicine.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute lung injury (ALI) and its severe form, acute respiratory distress syndrome (ARDS), are high-mortality respiratory diseases manifested by excessive inflammation and oxidative stress. Current therapies for ALI are limited by uncertain efficacy, severe side effects, restricted administration routes, or inadequate targeting capacity. Baicalein, a natural flavonoid with significant anti-inflammatory and antioxidant activity, shows promise for ALI. Unfortunately, its clinical application is limited by its low solubility and bioavailability. In this study, a novel baicalein liposome (BAPC-DLP) based on a baicalein‒phospholipid complex (BAPC) was constructed for nebulized inhalation. Comparative studies demonstrated that BAPC-DLP outperformed other baicalein-loaded liposomes in colloid stability, mucus penetration ability, and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.